BU-12 (Yttrium-90 anti-CD19 antibody)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BU-12 (Yttrium-90 anti-CD19 antibody), covering 2017-11-29 to 2017-11-29. Get the full timeline:
Most recent: Clinical Trial Update: Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia [Phase 1]